CA3053294A1 - Method for generating t cells progenitors - Google Patents
Method for generating t cells progenitors Download PDFInfo
- Publication number
- CA3053294A1 CA3053294A1 CA3053294A CA3053294A CA3053294A1 CA 3053294 A1 CA3053294 A1 CA 3053294A1 CA 3053294 A CA3053294 A CA 3053294A CA 3053294 A CA3053294 A CA 3053294A CA 3053294 A1 CA3053294 A1 CA 3053294A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- tnf
- alpha
- cell
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 110
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 104
- 210000004027 cell Anatomy 0.000 claims abstract description 256
- 239000003446 ligand Substances 0.000 claims abstract description 60
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims abstract description 44
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims abstract description 44
- 238000000338 in vitro Methods 0.000 claims abstract description 40
- 239000012634 fragment Substances 0.000 claims abstract description 37
- 108010067306 Fibronectins Proteins 0.000 claims abstract description 36
- 102000016359 Fibronectins Human genes 0.000 claims abstract description 36
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 claims abstract description 34
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 claims abstract description 34
- 239000005557 antagonist Substances 0.000 claims abstract description 19
- 238000012258 culturing Methods 0.000 claims abstract description 19
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 11
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract description 11
- BGFHMYJZJZLMHW-UHFFFAOYSA-N 4-[2-[[2-(1-benzothiophen-3-yl)-9-propan-2-ylpurin-6-yl]amino]ethyl]phenol Chemical compound N1=C(C=2C3=CC=CC=C3SC=2)N=C2N(C(C)C)C=NC2=C1NCCC1=CC=C(O)C=C1 BGFHMYJZJZLMHW-UHFFFAOYSA-N 0.000 claims abstract description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract 10
- 239000002609 medium Substances 0.000 claims description 47
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 102000004127 Cytokines Human genes 0.000 claims description 25
- 108090000695 Cytokines Proteins 0.000 claims description 25
- 239000001963 growth medium Substances 0.000 claims description 24
- 108010002586 Interleukin-7 Proteins 0.000 claims description 21
- 108010041111 Thrombopoietin Proteins 0.000 claims description 21
- 102000036693 Thrombopoietin Human genes 0.000 claims description 20
- 229940100994 interleukin-7 Drugs 0.000 claims description 20
- 210000000130 stem cell Anatomy 0.000 claims description 20
- 239000002243 precursor Substances 0.000 claims description 18
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 claims description 15
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 14
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 14
- 239000003102 growth factor Substances 0.000 claims description 12
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 11
- 229960002897 heparin Drugs 0.000 claims description 11
- 229920000669 heparin Polymers 0.000 claims description 11
- 238000010361 transduction Methods 0.000 claims description 10
- 230000026683 transduction Effects 0.000 claims description 10
- 101000829980 Homo sapiens Ral guanine nucleotide dissociation stimulator Proteins 0.000 claims description 9
- 102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 claims description 9
- 238000010362 genome editing Methods 0.000 claims description 8
- 108010056030 retronectin Proteins 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000001890 transfection Methods 0.000 claims description 6
- 230000003750 conditioning effect Effects 0.000 claims description 4
- 238000010253 intravenous injection Methods 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 102100034195 Thrombopoietin Human genes 0.000 claims description 3
- 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 claims description 2
- 102000000704 Interleukin-7 Human genes 0.000 claims 4
- 101710113649 Thyroid peroxidase Proteins 0.000 claims 2
- 108010070047 Notch Receptors Proteins 0.000 description 47
- 102000005650 Notch Receptors Human genes 0.000 description 47
- 210000004700 fetal blood Anatomy 0.000 description 47
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 28
- 230000004069 differentiation Effects 0.000 description 27
- 239000003550 marker Substances 0.000 description 20
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 230000008707 rearrangement Effects 0.000 description 18
- 102100021592 Interleukin-7 Human genes 0.000 description 16
- 101710178046 Chorismate synthase 1 Proteins 0.000 description 14
- 101710152695 Cysteine synthase 1 Proteins 0.000 description 14
- 102100032831 Protein ITPRID2 Human genes 0.000 description 14
- 210000005259 peripheral blood Anatomy 0.000 description 14
- 239000011886 peripheral blood Substances 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091008874 T cell receptors Proteins 0.000 description 10
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 9
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 239000013603 viral vector Substances 0.000 description 8
- 239000011324 bead Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- LKTNEXPODAWWFM-UHFFFAOYSA-N 2-methyl-N-[2-methyl-4-(2-methylphenyl)azophenyl]-3-pyrazolecarboxamide Chemical compound CC1=CC=CC=C1N=NC(C=C1C)=CC=C1NC(=O)C1=CC=NN1C LKTNEXPODAWWFM-UHFFFAOYSA-N 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 210000001978 pro-t lymphocyte Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 5
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 5
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 5
- 102100039064 Interleukin-3 Human genes 0.000 description 5
- 108010002386 Interleukin-3 Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108700012920 TNF Proteins 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- VFMMPHCGEFXGIP-UHFFFAOYSA-N 7,8-Benzoflavone Chemical compound O1C2=C3C=CC=CC3=CC=C2C(=O)C=C1C1=CC=CC=C1 VFMMPHCGEFXGIP-UHFFFAOYSA-N 0.000 description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 description 4
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 4
- 108010089975 arginyl-glycyl-aspartyl-serine Proteins 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 208000024908 graft versus host disease Diseases 0.000 description 4
- 108010044426 integrins Proteins 0.000 description 4
- 102000006495 integrins Human genes 0.000 description 4
- 229940076264 interleukin-3 Drugs 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000002992 thymic effect Effects 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 description 3
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 description 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 3
- -1 SCF Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 108700041286 delta Proteins 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 238000003182 dose-response assay Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000007813 immunodeficiency Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000066 myeloid cell Anatomy 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 101150083745 preT gene Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- WUWFDVDASNSUKP-UHFFFAOYSA-N 2-(2,4-dimethoxyphenyl)-6-methoxychromen-4-one Chemical compound COC1=CC(OC)=CC=C1C1=CC(=O)C2=CC(OC)=CC=C2O1 WUWFDVDASNSUKP-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102100034283 Annexin A5 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 101000994439 Danio rerio Protein jagged-1a Proteins 0.000 description 1
- 102100033553 Delta-like protein 4 Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- 101000994369 Homo sapiens Integrin alpha-5 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 102100032817 Integrin alpha-5 Human genes 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100032702 Protein jagged-1 Human genes 0.000 description 1
- 102100032733 Protein jagged-2 Human genes 0.000 description 1
- 101710170213 Protein jagged-2 Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108091005956 Type II transmembrane proteins Proteins 0.000 description 1
- 101710123661 Venom allergen 5 Proteins 0.000 description 1
- 208000010796 X-linked adrenoleukodystrophy Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000003783 cell cycle assay Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 102000044457 human DLL4 Human genes 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 108091006058 immobilized fusion proteins Proteins 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305161.6 | 2017-02-13 | ||
| EP17305161 | 2017-02-13 | ||
| PCT/EP2018/053406 WO2018146297A1 (en) | 2017-02-13 | 2018-02-12 | Method for generating t cells progenitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3053294A1 true CA3053294A1 (en) | 2018-08-16 |
Family
ID=58185453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3053294A Pending CA3053294A1 (en) | 2017-02-13 | 2018-02-12 | Method for generating t cells progenitors |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US20200046767A1 (enExample) |
| EP (2) | EP3580330B1 (enExample) |
| JP (2) | JP7164798B2 (enExample) |
| KR (1) | KR102666158B1 (enExample) |
| CN (1) | CN110506110B (enExample) |
| AU (1) | AU2018217404B2 (enExample) |
| BR (1) | BR112019016672A8 (enExample) |
| CA (1) | CA3053294A1 (enExample) |
| DK (1) | DK3580330T3 (enExample) |
| ES (1) | ES2931530T3 (enExample) |
| HU (1) | HUE060548T2 (enExample) |
| IL (1) | IL268641B2 (enExample) |
| MA (1) | MA47541A (enExample) |
| PL (1) | PL3580330T3 (enExample) |
| PT (1) | PT3580330T (enExample) |
| WO (1) | WO2018146297A1 (enExample) |
| ZA (1) | ZA201905470B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL268641B2 (en) * | 2017-02-13 | 2024-10-01 | Assist Publique Hopitaux Paris Aphp | Method for generating t cells progenitors |
| US20200308540A1 (en) * | 2017-09-29 | 2020-10-01 | Regents Of The University Of Minnesota | Methods of making, expanding, and using a human progenitor t cell |
| CN112041431A (zh) | 2018-02-14 | 2020-12-04 | 桑尼布鲁克研究所 | 产生t细胞谱系细胞的方法 |
| CA3109546A1 (en) * | 2018-09-07 | 2020-03-12 | Wisconsin Alumni Research Foundation | Generation of hematopoietic progenitor cells from human pluripotent stem cells |
| US20220315895A1 (en) * | 2019-05-01 | 2022-10-06 | Transfusion Health, Llc | Methods of making oligopotent and unipotent precursors |
| CA3144640A1 (en) * | 2019-06-24 | 2020-12-30 | Children's Hospital Los Angeles | Bcl11b overexpression to enhance human thymopoiesis and t cell function |
| CA3159629A1 (en) * | 2019-11-14 | 2021-05-20 | Peter William ZANDSTRA | Media formulations and methods for producing progenitor t cells |
| US20230159891A1 (en) * | 2020-03-31 | 2023-05-25 | Kyoto University | T cell progenitor production method |
| JP2023553313A (ja) | 2020-11-30 | 2023-12-21 | チョ ファーマ インコーポレイテッド | 細胞を富化するための抗体 |
| CA3213581A1 (en) * | 2021-05-25 | 2022-12-01 | Kai Ling LIANG | Generating t cell precursors via agonizing tumor necrosis factor receptor 2 |
| EP4426319A1 (en) | 2021-11-04 | 2024-09-11 | APHP (Assistance Publique - Hôpitaux de Paris) | Method for generating nk cells |
| FR3130843A1 (fr) * | 2021-12-21 | 2023-06-23 | Universite Claude Bernard Lyon 1 | Cellule progéniteur des lymphocytes T exprimant de manière régulée un transgène d’intérêt |
| AU2024211048A1 (en) | 2023-01-27 | 2025-08-07 | Notch Therapeutics (Canada), Inc. | Method for generating t cell lineage populations from stem/progenitor cells |
| WO2024175738A1 (en) * | 2023-02-22 | 2024-08-29 | Smart Immune | Method for thymus regeneration |
| US20250332260A1 (en) | 2024-04-10 | 2025-10-30 | Garuda Therapeutics, Inc. | Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations |
| WO2025219552A1 (en) | 2024-04-17 | 2025-10-23 | Assitance Publique Hopitaux De Paris | Method for producing t cell progenitors from human pluripotent stem cells |
| CN119709836B (zh) * | 2024-12-21 | 2025-08-08 | 湖南农业大学 | OsProT2基因在调控水稻镉含量、镉耐受性及产量中的应用和方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6093531A (en) | 1997-09-29 | 2000-07-25 | Neurospheres Holdings Ltd. | Generation of hematopoietic cells from multipotent neural stem cells |
| JP2001525176A (ja) | 1997-12-04 | 2001-12-11 | デューク・ユニバーシティー | Ｃｄ７＋ｃｄ３４−ｌｉｎ−造血細胞を単離し、使用する方法 |
| US10059923B2 (en) | 2008-01-30 | 2018-08-28 | Memorial Sloan Kettering Cancer Center | Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors |
| RU2535966C2 (ru) | 2008-09-12 | 2014-12-20 | Криопрашис Криобиоложия Лтда. | Клеточная терапия ишемической ткани |
| US8772028B2 (en) * | 2008-11-07 | 2014-07-08 | Sunnybrook Health Sciences Centre | CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of using |
| WO2011068962A1 (en) | 2009-12-03 | 2011-06-09 | The University Of Utah Research Foundation | Methods for generating t lymphocytes from hematopoietic stem cells |
| US20130095079A1 (en) | 2010-04-09 | 2013-04-18 | Fred Hutchinson Cancer Research Center | Compositions and methods for providing hematopoietic function without hla matching |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| US9834755B2 (en) * | 2011-12-08 | 2017-12-05 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
| WO2014110353A1 (en) | 2013-01-11 | 2014-07-17 | The Trustees Of The University Of Pennsylvania | Notch ligand bound bicompatible substrates and their use in bone formation |
| EP3027755B1 (en) * | 2013-08-02 | 2019-10-09 | The Regents of The University of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
| US20170128556A1 (en) | 2013-12-26 | 2017-05-11 | Thyas Co. Ltd. | Immunotherapy using t precursor cells derived from pluripotent stem cells having rearranged t cell receptor genes |
| KR20160145802A (ko) | 2014-04-23 | 2016-12-20 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법 |
| US10131876B2 (en) * | 2014-04-24 | 2018-11-20 | Miltenyi Biotec Gmbh | Method for automated generation of genetically modified T cells |
| WO2016039933A1 (en) | 2014-09-11 | 2016-03-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lentiviral vector for treating hemoglobin disorders |
| FR3026744B1 (fr) * | 2014-10-06 | 2024-04-19 | Hopitaux Paris Assist Publique | Methode de generation de progeniteurs de cellules t |
| WO2016205680A1 (en) * | 2015-06-17 | 2016-12-22 | The Uab Research Foundation | Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage |
| EP3440198A4 (en) | 2016-04-08 | 2019-11-06 | The Governing Council of the Universtiy of Toronto | PROCESS FOR THE PRODUCTION OF PRE-TREATMENT T CELLS FROM TRUNK AND / OR PRECURSOR CELLS AND USE THEREOF |
| IL268641B2 (en) * | 2017-02-13 | 2024-10-01 | Assist Publique Hopitaux Paris Aphp | Method for generating t cells progenitors |
-
2018
- 2018-02-12 IL IL268641A patent/IL268641B2/en unknown
- 2018-02-12 US US16/485,488 patent/US20200046767A1/en not_active Abandoned
- 2018-02-12 PT PT187045513T patent/PT3580330T/pt unknown
- 2018-02-12 AU AU2018217404A patent/AU2018217404B2/en active Active
- 2018-02-12 ES ES18704551T patent/ES2931530T3/es active Active
- 2018-02-12 BR BR112019016672A patent/BR112019016672A8/pt unknown
- 2018-02-12 MA MA047541A patent/MA47541A/fr unknown
- 2018-02-12 DK DK18704551.3T patent/DK3580330T3/da active
- 2018-02-12 EP EP18704551.3A patent/EP3580330B1/en active Active
- 2018-02-12 HU HUE18704551A patent/HUE060548T2/hu unknown
- 2018-02-12 JP JP2019565052A patent/JP7164798B2/ja active Active
- 2018-02-12 EP EP22158116.8A patent/EP4067482A1/en active Pending
- 2018-02-12 PL PL18704551.3T patent/PL3580330T3/pl unknown
- 2018-02-12 CA CA3053294A patent/CA3053294A1/en active Pending
- 2018-02-12 CN CN201880024963.1A patent/CN110506110B/zh active Active
- 2018-02-12 WO PCT/EP2018/053406 patent/WO2018146297A1/en not_active Ceased
- 2018-02-12 KR KR1020197024529A patent/KR102666158B1/ko active Active
-
2019
- 2019-08-19 ZA ZA2019/05470A patent/ZA201905470B/en unknown
-
2020
- 2020-09-02 US US17/010,208 patent/US11426430B2/en active Active
-
2021
- 2021-02-11 US US17/173,632 patent/US11638723B2/en active Active
- 2021-02-11 US US17/173,668 patent/US11642376B2/en active Active
-
2022
- 2022-09-28 JP JP2022154550A patent/JP2022185024A/ja active Pending
-
2023
- 2023-04-06 US US18/296,623 patent/US20230293586A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230293586A1 (en) | Method for generating t cells progenitors | |
| Shankar et al. | Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies | |
| Matosevic | Viral and nonviral engineering of natural killer cells as emerging adoptive cancer immunotherapies | |
| US12071635B2 (en) | Method for generating T-cell progenitors | |
| US20190062694A1 (en) | Manufacture and Cryopreservation of Fucosylated Cells for Therapeutic Use | |
| Netsrithong et al. | Advances in adoptive cell therapy using induced pluripotent stem cell-derived T cells | |
| ES2409128T3 (es) | Procedimientos de mejora de anidamiento e injerto de células madre | |
| TW202216174A (zh) | 使ｎｋ細胞與抗體之結合穩定化之方法及其利用 | |
| HK40081656A (en) | Method for generating t cells progenitors | |
| RU2797260C2 (ru) | Способ получения предшественников т-клеток | |
| HK40017982A (en) | Method for generating t cells progenitors | |
| HK40017982B (en) | Method for generating t cells progenitors | |
| WO2025220666A1 (en) | Cytotoxic Lymphocytes Expressing Variable Region-Deleted T Cell Receptors | |
| Shukla | Controlled generation of progenitor T-Cells from hematopoietic stem cells and pluripotent stem cells | |
| Guerrettaz | Aging-associated changes in B-lymphopoiesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230210 |
|
| EEER | Examination request |
Effective date: 20230210 |
|
| EEER | Examination request |
Effective date: 20230210 |